Prothena | PRTA - Net Income


Prothena reported $-18.58M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Agios Pharmaceuticals USD -100.7M 1.59M Jun/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 16.29M 15.79M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Exelixis USD 218.1M 6.04M Sep/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD -784.8M 1.37B Sep/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
MacroGenics USD 19.52M 56.29M Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Prothena USD -18.58M 51.3M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026